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Abstract
One component of host defense at mucosal surfaces seems to be epithelium-derived
antimicrobial peptides. Antimicrobial peptides are classified on the basis of their structure
and amino acid motifs. Peptides of the defensin, cathelicidin, and histatin classes are found
in humans. In the airways, a-defensins and the cathelicidin LL-37/hCAP-18 originate from
neutrophils. b-Defensins and LL-37/hCAP-18 are produced by the respiratory epithelium
and the alveolar macrophage and secreted into the airway surface fluid. Beside their direct
antimicrobial function, antimicrobial peptides have multiple roles as mediators of
inflammation with effects on epithelial and inflammatory cells, influencing such diverse
processes as proliferation, immune induction, wound healing, cytokine release, chemotaxis,
protease–antiprotease balance, and redox homeostasis. Further, antimicrobial peptides
qualify as prototypes of innovative drugs that might be used as antibiotics, anti-
lipopolysaccharide drugs, or modifiers of inflammation.
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Introduction
The survival of a multicellular organism in a world laden
with microorganisms depends on a network of host
defense mechanisms, involving several levels of interacting
systems. The initial contact of pathogenic microorganisms
with the host usually takes place at inner or outer body sur-
faces. The surface of the airways is a primary site for the
deposition and introduction of microorganisms, mainly
through inspired air. Several possible consequences result
from the contact of microorganisms with host tissue:
1. The invading microorganisms are eliminated by innate
host defense mechanisms without an inflammatory
response or the activation of adaptive immunity. This
normally happens in the lower respiratory tract and
occurs within a short time.
2. The microbe outgrows the innate host defense. As a
consequence, effector mechanisms of the innate
immune system are upregulated and have direct antimi-
crobial activity and mediator function to attract inflam-
matory cells and cells of the adaptive immune system.Respiratory Research    Vol 1 No 3 Bals
These mechanisms finally result in the elimination of the
microorganisms. In this scenario, the innate host
defense keeps the doubling time of the microorganisms
long enough to avoid an overwhelming of the immune
system.
3. The microorganism outgrows innate and adaptive
immunity. Together with a strong inflammatory response
this situation leads to the death of the host.
4. Microorganisms with specific physiological adaptations
can colonize the airways for a long time. In this case the
activities of the immune system are insufficient to elimi-
nate the invader.
Recent studies have shown that antimicrobial peptides are
expressed in human airways and are involved in the host
defense. Antimicrobial peptides are effector molecules of
innate immunity with direct antimicrobial and mediator
function. They have an important role in all scenarios
described above by providing an initial host defense
mechanism. It is the aim of this review article to describe
antimicrobial peptides as an endogenous part of the
innate immune system, to summarize the structures of
their genes and peptide molecules and to comment on
their role in health and disease.
Antimicrobial peptides as effector substances
of the innate immune system
A first line of defense against pathogenic insult is called
the innate immune system, which is followed by acquired
immune responses associated with the activation of T and
B cells aimed against specific antigens [1,2•]. In contrast
to the clonal, acquired adaptive immunity, endogenous
peptide antibiotics provide a fast and energy-effective
mechanism as front-line defense. In the respiratory tract,
the innate defense system of the host is complemented by
several other mechanisms to protect the airways and the
lung parenchyma from colonization and infection (Fig. 1).
Components of the airway surface fluid (ASF) with antimi-
crobial activity are lysozyme, lactoferrin, secretory phos-
pholipase A2, secretory leukocyte protease inhibitor
(SLPI), and antimicrobial peptides. Other substances,
such as complement, surfactant proteins, and Clara-cell
protein (CC10, CCSP), contribute to the host defense [3].
Mucus secreted by mucous gland and goblet cells
entraps particles that are then propelled by the movement
of cilia and probably provides a microenvironment neces-
sary for the activity of antimicrobial substances.
Essential to innate immunity are receptors that recognize
colonizing or invading microorganisms and initiate a host
defense reaction [1,2•]. Homology studies of lipopolysac-
charide (LPS)-binding receptors and signal transduction
cascades between insects and mammals (Toll and Toll-
like receptors, respectively) have revealed detailed
insights into certain aspects of the host defense system
and attracted a large amount of interest in innate immunity
during recent years [4,5]. Antimicrobial peptides have
emerged as potential participants in host defense at
mucosal surfaces such as the airways.
Basic biology of antimicrobial peptides
Families of human antimicrobial peptides
Most antimicrobial peptides are cationic (polar) molecules
with spatially separated hydrophobic and charged regions.
These structural hallmarks are important for the proposed
mechanisms of action of peptide antibiotics (see below).
Beside these characteristics, antimicrobial peptides of
various families differ in size, amino acid sequence and
certain structural motifs (Fig. 2). Antimicrobial peptides are
gene-encoded, meaning that one gene codes for one
peptide. Families of antimicrobial peptide genes are
located in clustered arrangements in the genome and map
to syntenic chromosomal regions in different mammalian
species, providing clues about the evolutionary develop-
ment of this host defense system. The primary translational
product is a prepropeptide consisting of an N-terminal
signal sequence for targeting of the endoplasmic reticu-
lum, a pro segment, and a C-terminal cationic peptide that
has antimicrobial activity after cleavage (Fig. 3). The pro
segment is often anionic in charge and might have several
biological functions including the correct folding of the
C-terminus, intracellular trafficking, or the inhibition of the
Figure 1
Host defense mechanisms of the respiratory epithelium. Coughing and
cilia mechanically remove inhaled debris and microorganisms
entrapped in mucus, a mechanism called mucociliary clearance.
Multiple substances with proinflammatory and anti-inflammatory as well
as antimicrobial activities are secreted by epithelial and inflammatory
cells and function as effector substances of the innate immune system.
Natural killer cells, dendritic cells, neutrophils, and macrophages
represent the cellular components of innate immunity. Cells of the
respiratory epithelium (1=ciliated cell, 2=goblet cell, 3=basal cell,
4=mucous and serous gland cells) are not passive bystanders of an
inflammatory process but secrete effector molecules including
antimicrobial peptides. The adaptive immune response with its T cells
and B cells (sIgA=secretory immunoglobulin A) is triggered by innate
mechanisms .c
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activity of the mature peptide. The propeptide is cleaved
off during later stages of intracellular processing or after
secretion into the extracellular space.
Antimicrobial peptides are stored as propeptides or
mature C-terminal peptides. In addition to positively
charged antimicrobial peptides, peptide antibiotics with a
negative charge at neutral pH have also been identified
[6]. These peptides seem to originate as cleavage prod-
ucts from larger proteins and are beyond the scope of this
review. Antimicrobial peptides can be grouped according
to their size, conformational structure, or predominant
amino acid structure. On the basis of their gross composi-
tion and three-dimensional structure, peptide antibiotics
are divided into three main classes (Fig. 2): group I, linear,
a-helical peptides without cysteines, for instance
cecropins from pig, magainins from frogs, LL-37/hCAP-18
from human; group II, peptides with an even number of
cysteine residues linked by disulfide bridges, for instance
defensins from mammals, protegrins (porcine catheli-
cidins); and group III, peptides with an unusually high pro-
portion of one or two amino acids, for instance PR-39
from pig leukocytes.
On the basis of structural homology motifs, a different
classification of families of antimicrobial peptides can
Figure 2
Classification of antimicrobial peptides based on motifs in the amino acid sequence similar to that described by Boman [63]. Antimicrobial
peptides could also be grouped according to other principles. LL-37 and PR-39 belong to the cathelicidin family on the basis of their homologous
propeptide. rTD-1=rhesus monkey q-defensin 1; PR-39=cathelicidin from pig. Human b-defensin 3 (hBD-3) was identified by using bioinformatic
screening procedures to search human chromosome 8p23 for the presence of sequence motifs typical of b-defensin (R Bals, unpublished data).be generated that reflects relationships between family
members. In humans, peptide antibiotics of three fami-
lies have been identified: the defensins, cathelicidins,
and histatins.
Defensins
Mammalian defensins are cationic, relatively arginine-rich
nonglycosylated peptides with a molecular mass of
3.5–4.5 kDa and contain six cysteine residues that form
three characteristic intramolecular disulfide bridges [7].
According to the spacing of the cysteines, the alignment
of the disulfide bridges, and the overall molecular struc-
ture, defensins can be divided into three classes:
a-defensins, b-defensins, and q-defensins.
a-Defensins.  a-Defensins are 29–35 residues in length,
contain three disulfide bridges in a 1–6, 2–4, 3–5 alignment,
and reveal a triple-stranded bsheet structure with a bhairpin
that contains cationic amino acids (Fig. 2). The first human
a-defensin was isolated from neutrophils in 1985 [8]. So far,
six a-defensins have been identified from humans. Human
neutrophil peptides 1–4 (HNP-1 to HNP-4) are localized in
azurophilic granules of neutrophil granulocytes, where they
are the principal protein and contribute to the oxygen-inde-
pendent killing of phagocytized microorganisms [8,9]. The
two other a-defensins, human defensins 5 and 6, are primar-
ily found in Paneth’s cells of the small intestine and epithelial
cells of the female urogenital tract [10].
The genes encoding a-defensins and b-defensins are
located in a cluster on chromosome 8p23 [11]. The gene
for HNP-2 has not been found at this location, indicating
that HNP-2 is a proteolytic product of HNP-1 or HNP-3.
a-defensins are produced as prepropeptides (Fig. 3). A
recent report from Wilson et al [12•] revealed insight into
the processing of murine cryptins, a-defensins found in
Paneth’s cells of the small intestine. The disruption of the
gene for matrilysin (MMP7), a tissue metalloprotease, in a
knockout mouse model prevented the cleavage of the
propeptide of cryptins, resulting in increased susceptibility
of the animals to bacterial infection. Cleavage of the
propeptide takes place in the lumen of the intestinal crypts
where antimicrobial peptides are present in high concen-
trations together with the secreted MMP7. The source of
peptides HNP-1 to HNP-4, which are found in abundance
in the ASF of inflamed airways, are neutrophils that have
migrated into the airway walls or lumen [13].
b-Defensins. In 1991 Diamond et al [14••] isolated an
antimicrobial peptide from cow tongue, called tracheal
Respiratory Research    Vol 1 No 3 Bals
Figure 3
Structure of prototypical genes and peptides of the defensin and cathelicidin families. Both gene types have several exons whose primary
translational product is a prepropeptide. The C-terminus is the part of the molecules that contains antimicrobial activity. The genes are represented
schematically with the following individual components: 5¢ untranslated region (5¢ UTR), white box; signal sequence, shaded box; prosequence,
black box; mature peptide, hatched box; 3¢ UTR, white box.antimicrobial peptide (TAP), which contains six cysteine
residues connected by three disulfide bridges but spaced
differently from those in a-defensins. This new family of
antimicrobial peptides was therefore named b-defensins;
they are 36–42 residues in length, possess a disulfide
alignment of 1–5, 2–4, 3–6, and have been isolated from
several species (Fig. 2). The first human b-defensin, called
human b-defensin-1 (hBD-1), was originally isolated from
large volumes of hemofiltrate [15•] and is expressed con-
stitutively in epithelial cells of the urinary and respiratory
tract [16•,17••,18]. Human b-defensin-2 (hBD-2) was iso-
lated from psoriatic skin by using an affinity chromatogra-
phy procedure applying columns coated with components
of  Escherichia coli [19•]. hBD-2 was found to be
expressed in epithelia of the inner or outer surfaces of the
human body, such as skin and the respiratory and gas-
trointestinal tract [20,21•].
Both human b-defensins have been isolated by means of
bioscreening, which applies functional assays to the
detection of the antimicrobial activity of candidate sub-
stances obtained from large amounts of biological mater-
ial. hBD-1 and hBD-2 are expressed diffusely throughout
the surface epithelium and the serous gland cells in the
airway walls. Both peptides have been detected in airway
secretions; concentrations are in the mg/ml range
[20,21•]. In contrast to hBD-2, which has been detected
only in its 41-residue form, hBD-1 has been detected in
urine in multiple forms ranging from 36 to 47 residues in
length [18]. The genes encoding b-defensins are localized
in the same chromosomal region as the a-defensins. The
gene for hBD-1 is separated from that for HNP-1 by about
100–150 kilobases [11]. The processing of b-defensins is
probably similar to that of a-defensins; however, no
detailed analysis has yet been published.
q-Defensins. Recently a novel class of defensins has been
isolated from rhesus monkey neutrophils and named
q-defensins for their circular molecular structure (Fig. 2)
[22••]. The peptide rhesus q-defensin-1 is produced by the
post-translational ligation of two truncated a-defensins
and demonstrates salt-independent antimicrobial activity.
Levels of these peptides in the airways have not been
determined. No data about the presence of these mole-
cules in the airways are available at this time.
Cathelicidins
Peptide antibiotics of the cathelicidin family contain a
highly conserved signal sequence and pro-region (‘cathe-
lin’=cathepsin L inhibitor) but show substantial hetero-
geneity in the C-terminal domain encoding the mature
peptide, which can range in size from 12 to 80 or more
amino acid residues [23] (Figs 2 and 3). The only human
cathelicidin, LL-37/hCAP-18, was isolated from human
bone marrow [24–26]. LL-37/hCAP-18 is expressed in
myeloid cells where it resides in granules but is also found
in inflamed skin. LL-37/hCAP-18 has been found to be reg-
ulated by inflammatory stimuli [27]. In the airways, the
peptide is produced by the same cell types as the
b-defensins and is secreted into the ASF [28•]. Addition-
ally, LL-37 originates from neutrophils that have invaded
the airways. LL-37 has been detected in tissue-culture
supernatants of respiratory epithelial cells as well as in lung
washings from patients [28•,29]. At present no details are
known about the processing of LL-37/hCAP-18 in epithe-
lial cells. In neutrophils, where LL-37/hCAP-18 is localized
to specific granules, the peptide is stored in its propeptide
form and cleaved during secretion, probably by the activity
of an elastase (Fig. 3). Beside its antimicrobial activity,
LL-37 binds and neutralizes LPS and protects against
endotoxic shock in a murine model of septicemia [30]. The
gene encoding LL-37/hCAP-18 consists of four exons and
is localized on chromosome 3.
Histatins
Histatins are a family of histidine-rich peptides present in
human saliva (Fig. 2) [31–33]. Their presence in airway
secretions has not been investigated. The primary struc-
tures of the major family members (histatins 1 and 3) has
been determined and revealed lengths of 38 and 32
amino acid residues. Smaller members of the histatin
family, including histatin 5 (24 residues), originate from
histatin 1 and 3 by post-translational processing. The
genes that encode histatins 1 and 3 consist of several
exons and have been mapped to human chromosome
4q13. The antimicrobial activity includes especially strong
antifungal effects.
Gene regulation
Because peptide antibiotics are host defense substances
with antimicrobial activity as well as a mediator function,
their expression is tightly regulated. The regulation of antimi-
crobial peptides has been described in detail for murine,
human, and bovine molecules. The expression of hBD-1 has
been found to be constitutive [20,34]. In contrast, hBD-2
expression has been detected to be upregulated by infec-
tious and inflammatory stimuli in cell cultures as well as in
human studies. In human material, hBD-2 transcripts and
peptide levels in the airways were upregulated during infec-
tion [35]. In cell culture experiments, hBD-2 expression was
stimulated by interleukin (IL)-1a, IL-1b, tumor necrosis
factor-a, microorganisms (Gram-positive and Gram-nega-
tive bacteria, and Candida albicans), and LPS [20,34,36].
These results are consistent with the detection of a consen-
sus NF-kB binding site upstream of the hBD-2 gene. In
addition, the expression of LL-37/hCAP-18 has been
reported to be upregulated in inflamed skin [27], where the
peptide is colocalized with IL-6 [37]. The gene encoding
LL-37/hCAP-18 contains several potential binding sites for
transcription factors [acute-phase response factor and
nuclear factor for IL-6 expression (NF IL-6)] that are possibly
involved in the regulation of gene expression.
http://respiratory-research.com/content/1/3/141
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and the nature of the corresponding receptors and sig-
nalling pathways are speculative at present. Airway epithe-
lial cells express several molecules that qualify as
receptors to detect infection or inflammation (reviewed in
[38]). It has been shown that these cells synthesize the
receptor panel to detect bacterial LPS, including CD14
and Toll-like receptors 1–9 ([39], and R Bals, unpublished
data). Intracellular signalling probably includes NF-kB, NF
IL-6, and JAK/STAT pathways. The airway epithelium is an
immune organ with the capabilities of detecting microor-
ganisms and inducing an inflammatory and host defense
response, including the secretion of antimicrobial peptides
as effector molecules. Antimicrobial peptides of the respi-
ratory tract might be induced by different stimuli and sig-
nalling pathways, and could have different functions as
effector molecules. This concept of a large family of
antimicrobial peptides with differential functions against
diverse classes of microorganisms has been demon-
strated for the host defense system of Drosophila [40]
and should also be applicable to humans.
Activities of antimicrobial peptides
The antimicrobial activity of peptide antibiotics was
deduced from tests in vitro assaying purified substances
against microorganisms. Antimicrobial peptides, including
defensins, cathelicidins and histatins, have a broad spec-
trum of activity against Gram-positive and Gram-negative
bacteria as well as against fungi and enveloped viruses.
The minimal inhibitory concentrations of the peptides are
in the range 0.1–100mg/ml. Antimicrobial peptides show
synergistic activity with other host defense molecules
such as lysozyme and lactoferrin. The microbicidal activity
of defensins stems from the permeabilization of anionic
lipid bilayers and the subsequent release of cellular con-
tents and the destruction of the membrane’s electrode
potential (Fig. 4).
The first step of the interaction between the cationic
peptide and the anionic microbial cell membrane is
thought to involve electrostatic attraction, which is inhib-
ited by high concentrations of salt in the solution. The
second step is the permeabilization of the membrane. One
mechanism of permeabilization is thought to involve the
formation of ion pores. The existence of pores, their
dimensions and electrical properties have been described
for model bilayers and various cell types [41,42]. A
second model, the so called ‘carpet’ model, has been pro-
posed for magainins, cecropine (antimicrobial peptides
from frog and pig, respectively), and hBD-2 [43] and
describes the aggregation of peptides into positively
charged patches of the membrane [44], resulting in the
formation of transient gaps. Additionally, defensin-related
cell death has been related to interference with protein
synthesis or DNA damage.
Functional studies on antimicrobial activity have primarily
been restricted to experiments in vitro with purified com-
ponents. In fact, the evidence that defensins actually con-
tribute to innate immunity in vivo is largely indirect.
Evidence for the host defense function of antimicrobial
peptides came from the above-mentioned study involving
MMP7 knockout mice with an increased susceptibility for
infections, which was probably due to the defective cleav-
age of a-defensins in the small intestine [12•]. In addition
to their antimicrobial activity, defensins and cathelicidins
can bind to lipopolysaccharide and inactivate the biologi-
cal functions of this endotoxin. Bacterial resistance to
antimicrobial peptides is a rare phenomenon. Mechanisms
that result in the development of resistance involve modifi-
cations of outer cell wall components, such as
lipopolysaccharide [45], teichoic acids [46], or phospho-
choline [47], and the modulation of efflux pumps [48].
Beside their role as endogenous antibiotics, antimicrobial
peptides have functions in inflammation, wound repair,
and regulation of the adaptive immune system (Fig. 4).
Human neutrophil defensins have been described as
being cytotoxic to various cell types [49•], as inducing
cytokine synthesis in airway epithelial cells [50], mono-
cytes [51], and T lymphocytes [52], as increasing the
release of SLPI from respiratory epithelial cells [53], and
Respiratory Research    Vol 1 No 3 Bals
Figure 4
Activities of antimicrobial peptides. As well as their antimicrobial
function (1), antimicrobial peptides have other potential roles in
inflammation and infection (2,3). The mechanism of the antimicrobial
activity is explained in the insert. After electrostatic interactions
between the negatively charged bacterial wall and the positively
charged peptides (a), the peptide associates with the membranes,
either by insertion as pores (b) or by forming carpet-like structures that
lead to a destabilization of the membrane. The sources (1) of
antimicrobial peptides in the airways are epithelial cells and
inflammatory cells. Defensins and LL-37 have a feedback mediator
function that targets these cell types (2,3), influencing the release of
mediators and other cellular processes such as proliferation and
chemoattraction.as decreasing intracellular glutathione concentration [54].
Further, they increase the binding of bacteria to epithelial
cells [55] and induce the liberation of histamine from mast
cells. Finally, a-defensins are involved in the chemotaxis of
monocytes and T cells [56], the modulation of cell prolifer-
ation and an antibody response, and the inhibition of com-
plement activation, of fibrinolysis and of the activity of
serpin family members (reviewed in [57]). The human
b-defensins have recently been identified as potent
ligands for the chemokine receptor CCR6 that is present
on dendritic and T cells, therefore providing a link between
innate and adaptive immunity [58•].
Role of antimicrobial peptides in health and
disease
Host defense function
On the basis of their activity in vitro, their patterns of
expression and gene regulation, and their involvement in
pathways of innate immunity, there is strong suggestive
evidence that antimicrobial peptides serve as host
defense substances not only by direct antimicrobial activ-
ity but also as mediators. Animal experiments with the use
of a human bronchial xenograft model with the genetic
depletion of hBD-1 by antisense oligonucleotides [17••],
overexpression of antimicrobial peptides in animal models
of infection [30], or the above-mentioned experiments with
matrilysin knockout mice [12•] support this view. An
assessment of the relative contribution of individual pro-
teins or peptides to the host defense is difficult to accom-
plish. The concentrations of antimicrobial peptides and
proteins at the site of action (e.g. in the gel or sol layer of
the ASF) is difficult to determine because of problems in
sampling the ASF. A functional analysis of purified pep-
tides and proteins in vitro does not reflect the complexity
of component interactions, such as synergism and antago-
nism between multiple substances.
Role of antimicrobial peptides in inflammatory lung diseases
The story of cystic fibrosis (CF) research over the past
decade has provided important lessons about the relation
between a defect in an ion channel and a breach of the
host defense system of the airways. An obvious defect of
the host defense system of the respiratory tract is evident
from clinical studies and was evaluated in several models
in vitro or ex vivo [17••,59••]. The link between the defect
in ion transport and decreased host defense is less
obvious and remains speculative at present (reviewed in
[60]). Antimicrobial peptides might have a role in this
pathogenesis, either by being inactivated by increased salt
concentration in secretions of CF airways or by being
absent from the ASF owing to alteration of the secretory
apparatus caused by the dysfunctional CF transmembrane
conductance regulator (CFTR).
Beside their host defense function during infections, the
proinflammatory activity of antimicrobial peptides is likely
to have negative consequences too. In CF patients, high
concentrations of a-defensins in lung washings have been
detected that are in the range of cytotoxicity [13]. Chronic
obstructive pulmonary disease (COPD) and other inflam-
matory lung diseases such as pulmonary fibrosis, a1-anti-
trypsin deficiency, acute respiratory distress syndrome, or
diffuse panbronchiolitis are often associated with the
release of antimicrobial peptides and inflammatory media-
tors from neutrophils and other cell types.
On the basis of the activities of antimicrobial peptides, it is
obvious that these substances affect the inflammatory
process (Fig. 4). Owing to the lack of detailed knowledge
of their functional spectrum in vivo, it is hard to decide
which peptide antibiotic in which concentration results in a
proinflammatory or anti-inflammatory activity. On the one
hand, defensins attract inflammatory cells such as neu-
trophils, B-cells, and macrophages, and activate these and
other cell types, including epithelial cells. They liberate
inflammatory mediators such as IL-8, interferon-g, IL-6,
IL-10, and LTB4. Defensins might lead to an imbalance of
the redox system by reducing glutathione levels in epithelial
airway cells and might disturb the protease–antiprotease
system by binding to proteinase inhibitor (serpin) family
members. On the other hand, defensins might also exhibit
anti-inflammatory activities by induction of the secretion of
IL-10 [61] or SLPI [53], or by facilitating the binding of
microorganisms to epithelia with subsequent clearance of
the microorganisms by a bactericidal activity of the cell.
It is also likely that antimicrobial peptides in the airway
secretions modulate the cytokine profile of lymphocytes
towards T helper type 1 or 2 cells. This could have a direct
effect on the development of bronchial hyper-responsive-
ness. Additionally, defensins have been shown to release
histamine from mast cells and might induce hyper-respon-
siveness by their cationic charge [62]. These experimental
results do not draw a complete picture of the functions
that antimicrobial peptides have in inflammatory or infec-
tious disease; however, they indicate that they fulfil not
only an epiphenomenal bystander role but are linked to the
underlying pathogenetic processes.
Antimicrobial peptides as drugs
The intriguing idea of developing antimicrobial peptides as
innovative antibiotics has been followed up by several
biotechnological companies. With the use of protein-bio-
chemical methods and recombinant DNA technology, the
structures of naturally occurring peptides serve as starting
points for the development of new drugs. Several deriva-
tives of antimicrobial peptides have been through the
pharmaceutical process, including human phase I–III
studies. The use of human antimicrobial peptides as drugs
is restricted so far by the still unknown biological function
of these molecules and the high costs of the generation of
sufficient amounts. On the basis of their functions that
http://respiratory-research.com/content/1/3/141
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hhave been elucidated so far, antimicrobial peptides might
not serve only as antibiotics, but also as modulators of
inflammation or anti-LPS medication.
Concluding remarks
Antimicrobial peptides have emerged as effector sub-
stances of the innate immune system involving activities
not only as endogenous antibiotics but also as mediators
of inflammation. Several important topics will have to be
addressed in the future:
1. The identification of novel antimicrobial peptides. It is
likely that human families of antimicrobial peptides
consist of multiple molecules. Progress in the Human
Genome Project will also reveal ways of shortcutting
conventional bioscreening procedures for the identifi-
cation of host defense substances.
2. Analysis of the biologically relevant functions of antimi-
crobial peptides. Beside experiments in vitro that give
the first molecular insight into the function of peptide
antibiotics, a broader approach involving genetic
animal models is necessary to interpret results in vitro
in the context of a whole organism.
3. Evaluation of the function of antimicrobial peptides in
airway (and other) diseases will provide insights into
the corresponding pathogenesis.
4. Development of antimicrobial peptides as drugs.
Studying the biology of antimicrobial peptides might
permit the development of novel therapeutics for infec-
tious or inflammatory diseases.
Acknowledgement
I thank Dr DJ Weiner for helpful discussions, and Professor G Steinbeck,
Professor JW Wilson, and Dr C Vogelmeier for their support. Studies in my
laboratory related to innate immunity of the respiratory tract are supported
by grants of the Deutsche Forschungsgemeinschaft (Ba 1641/3-1) and the
Friedrich-Baur-Stiftung.
References
Articles of particular interest have been highlighted as:
• of special interest
•• of outstanding interest
1. Fearon D, Locksley R: The instructive role of innate immunity in the
aquired immune response. Science 1996, 272:50–54.
2. Medzhitov R, Janeway CJ Jr: Advances in immunology: innate 
• immunity. N Engl J Med 2000, 343:338–344.
The authors review the recent developments in the field on innate immunity,
focusing on the identification of insect and mammalian receptors that recog-
nize microorganisms.
3. Wilmott R, Fiedler M, Stark J: Host defense mechanisms. In Disor-
ders of the Respiratory Tract in Children. Edited by Chernick V, Boat
TF. Philadelphia: Saunders; 1998:238–264.
4. Kopp E, Medzhitov R: The Toll-receptor family and control of innate
immunity. Curr Opin Immunol 1999, 11:13–18.
5. Modlin R, Brightbill H, Godowski P: The Toll of innate immunity on
microbial pathogenesis. New Engl J Med 1999, 340:1834–1835.
6. Brogden KA, Ackermann MR, McCray PB Jr, Huttner KM: Differences
in the concentrations of small, anionic, antimicrobial peptides in
bronchoalveolar lavage fluid and in respiratory epithelia of
patients with and without cystic fibrosis. Infect Immun 1999, 67:
4256–4259.
7. Lehrer R, Ganz T, Selsted M: Defesins: endogenous antibiotic pep-
tides of animal cells. Cell 1991, 64:229–230.
8. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF,
Lehrer RI: Defensins. Natural peptide antibiotics of human neu-
trophils. J Clin Invest 1985, 76:1427–1435.
9. Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI: Primary
structures of three human neutrophil defensins. J Clin Invest
1985,  76:1436–1439.
10. Quayle AJ, Porter EM, Nussbaum AA, Wang YM, Brabec C, Yip KP,
Mok SC: Gene expression, immunolocalization, and secretion of
human defensin-5 in human female reproductive tract. Am J
Pathol 1998,  152:1247–1258.
11. Linzmeier R, Ho CH, Hoang BV, Ganz T: A 450-kb contig of defensin
genes on human chromosome 8p23. Gene 1999, 233:205–211.
12. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, 
• Stratman JL, Hultgren SJ, Matrisian LM, Parks WC: Regulation of 
intestinal  a a-defensin activation by the metalloproteinase 
matrilysin in innate host defense. Science 1999, 286:113–117.
This paper reports results obtained from a murine knockout model indicat-
ing that defensins have host defense function in vivo. The metalloproteinase
matrilysin is involved in the extracellular cleavage and activation of mouse a-
defensins.
13. Soong L, Ganz T, Ellison A, Caughey G: Purification and characteri-
zation of defensins from cystic fibrosis sputum. Inflamm Res 1997,
46:98–102.
14. Diamond G, Zasloff M, Eck H, Brasseur M, Maloy WL, Bevins CL: Tra-
•• cheal antimicrobial peptide, a cysteine-rich peptide from mam-
malian tracheal mucosa: peptide isolation and cloning of a cDNA. 
Proc Natl Acad Sci USA 1991, 88:3952–3956.
A classic paper describing the first isolation of a b-defensin from mammalian
airways.
15. Bensch K, Raida M, Magert H-J, Schulz-Knappe P, Forssmann W-G: 
• hBD-1: a novel b b-defensin from human plasma. FEBS Lett 1995, 
368:331–335.
In this publication the peptide biochemical work is described that resulted in
the isolation of the first human b-defensin. This procedure, which used
several thousand litres of hemofiltrate, is an excellent example of the bio-
screening approach to the identification of human antimicrobial peptides.
16. McCray P Jr, Bentley L: Human airway epithelia express a 
• b b-defensin. Am J Respir Cell Mol Biol 1997, 16:343–349.
The authors describe the presence of hBD-1 in human airways.
17. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, 
•• Wilson JM: Human b b-defensin-1 is a salt-sensitive antibiotic in 
lung that is inactivated in cystic fibrosis. Cell 1997, 88:553–560.
This paper reports the detection of hBD-1 in human airways and links the
salt sensitive antimicrobial activity of this peptide to the pathogenesis of CF
lung disease. Beside the first description of the production of an antimicro-
bial peptide in human airway epithelial cells, this paper implies that
defensins have host defense functions by using an antisense strategy in a
human bronchial xenograft model.
18. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB Jr, Ganz T:
Human  b b-defensin-1: an antimicrobial peptide of urogenital
tissues. J Clin Invest 1998, 101:1633–1642.
19. Harder J, Bartels J, Christophers E, Schroeder J-M: A peptide antibi-
• otic from human skin. Nature 1997, 387:861.
Isolation of hBD-2 by using a bioscreening approach. This paper describes
sophisticated methods of isolating antimicrobial peptides from inflamed
psoriatic skin using columns coated with bacteria.
20. Singh P, Jia H, Wiles K, Hesselberth J, Liu L, Conway B, Greenberg E,
Valore E, Welsh M, Ganz T, Tack B, McCray PJ: Production of b b-
Respiratory Research    Vol 1 No 3 Balsdefensins by human airway epithelia. Proc Natl Acad Sci USA
1998,  95:14961–14966.
21. Bals R, Wang X, Wu Z, Freeman, Banfa V, Zasloff M, Wilson J: 
• Human  b b-defensin 2 is a salt-sensitive peptide antibiotic 
expressed in human lung. J Clin Invest 1998, 102:874–880.
This paper describes the presence and distribution of hBD-2 in human
airways as well as the activity of recombinant peptide against various
microorganisms.
22. Tang Y-Q, Yaun J, Osapay G, Osapay C, Tran D, Miller C, Quellette A, 
•• Selsted M: A cyclic antimicrobial peptide produced in primate 
leukocytes by the ligation of two truncated a a-defensins. Science
1999, 286:498–502.
These authors describe the isolation of a novel defensin molecule from
monkey neutrophils. The peptide was isolated by bioscreening methods and
revealed a cyclic structure.
23. Zanetti M, Gennaro R, Romeo D: Cathelicidins: a novel protein 
family with a common proregion and a variable C-terminal antimi-
crobial domain. FEBS Lett 1995, 374:1–5.
24. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B,
Salcedo R: The human gene FALL39 and processing of the cathe-
lin precursor to the antibacterial peptide LL-37 in granulocytes.
Eur J Biochem 1996, 238:325–332.
25. Cowland J, Johnsen A, Borregaard N: hCAP-18, a cathelin/pro-
bactenecin-like protein of human neutrophil specific granules.
FEBS Lett 1995, 368:173–176.
26. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmunds-
son GH: FALL-39, a putative human peptide antibiotic, is cysteine-
free and expressed in bone marrow and testis. Proc Natl Acad Sci
USA 1995, 92:195–199.
27. Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S,
Wigzell H, Gudmundsson GH: The expression of the gene coding
for the antibacterial peptide LL-37 is induced in human ker-
atinocytes during inflammatory disorders. J Biol Chem 1997,
272:15258–15263.
28. Bals R, Wang X, Zasloff M, Wilson JM: The peptide antibiotic 
• LL-37/hCAP-18 is expressed in epithelia of the human lung where 
it has broad antimicrobial activity at the airway surface. Proc Natl 
Acad Sci U S A 1998, 95:9541–9546.
This paper describes the presence and distribution of LL-37/hCAP-18 in
human airways as well as the activity of the recombinant peptide active
against various microorganisms. This is the first report on the presence of
cathelicidin antimicrobial peptides in human mucosal tissues.
29. Agerberth B, Grunewald J, Castanos-Velez E, Olsson B, Jornvall H,
Wigzell H, Eklund A, Gudmundsson GH: Antibacterial components
in bronchoalveolar lavage fluid from healthy individuals and sar-
coidosis patients. Am J Respir Crit Care Med 1999, 160:283–290.
30. Bals R, Weiner D, Moscioni A, Meegalla R, Wilson J: Augmentation
of innate host defense by expression of a cathelicidin antimicro-
bial peptide. Infect Immun 1999, 67:6084–6089.
31. Oppenheim FG, Xu T, McMillian FM, Levitz SM, Diamond RD, Offner
GD, Troxler RF: Histatins, a novel family of histidine-rich proteins
in human parotid secretion. Isolation, characterization, primary
structure, and fungistatic effects on Candida albicans. J Biol Chem
1988, 263:7472–7477.
32. vanderSpek JC, Wyandt HE, Skare JC, Milunsky A, Oppenheim FG,
Troxler RF: Localization of the genes for histatins to human chro-
mosome 4q13 and tissue distribution of the mRNAs. Am J Hum
Genet 1989, 45:381–387.
33. vanderSpek JC, Offner GD, Troxler RF, Oppenheim FG: Molecular
cloning of human submandibular histatins. Arch Oral Biol 1990,
35:137–143.
34. O’Neil DA, Porter EM, Elewaut D, Anderson GM, Eckmann L, Ganz T,
Kagnoff MF: Expression and regulation of the human b b-defensins
hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999, 163:
6718–6724.
35. Hiratsuka T, Nakazato M, Date Y, Ashitani J, Minematsu T, Chino N,
Matsukura S: Identification of human b b-defensin-2 in respiratory
tract and plasma and its increase in bacterial pneumonia. Biochem
Biophys Res Commun 1998, 249:943–947.
36. Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J,
Maune S, Schroder JM: Mucoid Pseudomonas aeruginosa, TNF-a a,
and IL-1b b, but not IL-6, induce human b b-defensin-2 in respiratory
epithelia. Am J Respir Cell Mol Biol 2000, 22:714–721.
37. Frohm Nilsson M, Sandstedt B, Sorensen O, Weber G, Borregaard N,
Stahle-Backdahl M: The human cationic antimicrobial protein
(hCAP18), a peptide antibiotic, is widely expressed in human
squamous epithelia and colocalizes with interleukin-6. Infect
Immun 1999,  67:2561–2566.
38. Diamond G, Legarda D, Ryan LK: The innate immune response of
the respiratory epithelium. Immunol Rev 2000, 173:27–38.
39. Becker MN, Diamond G, Verghese MW, Randell SH: CD14-depen-
dent LPS-induced b b-defensin-2 expression in human tracheo-
bronchial epithelium. J Biol Chem 2000, 275:29731–29736.
40. Lemaitre B, Reichhart JM, Hoffmann JA: Drosophila host defense:
differential induction of antimicrobial peptide genes after infection
by various classes of microorganisms. Proc Natl Acad Sci U S A
1997, 94:14614–14619.
41. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME: Inter-
action of human defensins with Escherichia coli. Mechanism of
bactericidal activity. J Clin Invest 1989, 84:553–561.
42. Lencer W, Cheung G, Strohmeier G, Currie M, Ouellette A, Selsted
M, Madara J: Induction of epithelial chloride secretion by channel-
forming cryptdins 2 and 3. Proc Natl Acad Sci USA 1997, 94:
8585–8589.
43. Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ,
Chertov O, Lubkowski J: The structure of human b b-defensin-2
shows evidence of higher-order oligomerization. J Biol Chem
2000,  275:32911–32918.
44. Ludtke SJ, He K, Heller WT, Harroun TA, Yang L, Huang HW: Mem-
brane pores induced by magainin. Biochemistry 1996, 35:13723–
13728.
45. Ernst RK, Yi EC, Guo L, Lim KB, Burns JL, Hackett M, Miller SI: Spe-
cific lipopolysaccharide found in cystic fibrosis airway
Pseudomonas aeruginosa. Science 1999, 286:1561–1565.
46. Peschel A, Otto M, Jack R, Kalbacher H, Jung G, Götz F: Inactivation
of the dlt operon in Staphylococcus aureus confers sensitivity to
defensins, protegrins, and other antimicrobial peptides. J Biol
Chem 1999,  274:8405–8410.
47. Lysenko ES, Gould J, Bals R, Wilson JM, Weiser JN: Bacterial phos-
phorylcholine decreases susceptibility to the antimicrobial
peptide LL-37/hCAP18 expressed in the upper respiratory tract.
Infect Immun 2000, 68:1664–1671.
48. Shafer WM, Qu X, Waring AJ, Lehrer RI: Modulation of Neisseria
gonorrhoeae susceptibility to vertebrate antibacterial peptides
due to a member of the resistance/nodulation/division efflux
pump family. Proc Natl Acad Sci USA 1998, 95:1829–1833.
49. Van Wetering S, Mannesse-Lazeroms SP, Dijkman JH, Hiemstra PS: 
• Effect of neutrophil serine proteinases and defensins on lung 
epithelial cells: modulation of cytotoxicity and IL-8 production. J 
Leukoc Biol 1997, 62:217–226.
This paper reports proinflammatory activities of a-defensins beside the
direct antimicrobial function. This report indicates strongly that antimicrobial
peptides are involved in inflammatory processes in the airways.
http://respiratory-research.com/content/1/3/141
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h50. Van Wetering S, Mannesse-Lazeroms SP, Van Sterkenburg MA, Daha
MR, Dijkman JH, Hiemstra PS: Effect of defensins on interleukin-8
synthesis in airway epithelial cells. Am J Physiol Lung Cell Mol
Physiol 1997,  272:L888–L896.
51. Territo MC, Ganz T, Selsted ME, Lehrer R: Monocyte-chemotactic
activity of defensins from human neutrophils. J Clin Invest 1989,
84:2017–2020.
52. Chertov O, Michiel DF, Xu L, Wang JM, Tani K, Murphy WJ, Longo DL,
Taub DD, Oppenheim JJ: Identification of defensin-1, defensin-2,
and CAP37/azurocidin as T-cell chemoattractant proteins
released from interleukin-8-stimulated neutrophils. J Biol Chem
1996,  271:2935–2940.
53. van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer WI,
Kuijpers AL, Schalkwijk J, Hiemstra PS: Regulation of SLPI and
elafin release from bronchial epithelial cells by neutrophil
defensins. Am J Physiol Lung Cell Mol Physiol 2000, 278:L51–L58.
54. Van Wetering S, Rahman I, Hiemstra PS, MacNee W: Role of intra-
cellular glutathione in neutrophil defensin-induced IL-8 synthesis
and cytotoxicity in airway epithelial cells. Eur Respir J 1998, 12:
420s.
55. Gorter AD, Eijk PP, van Wetering S, Hiemstra PS, Dankert J, van
Alphen L: Stimulation of the adherence of Haemophilus influenzae
to human lung epithelial cells by antimicrobial neutrophil
defensins. J Infect Dis 1998, 178:1067–1074.
56. Yang D, Chen Q, Chertov O, Oppenheim JJ: Human neutrophil
defensins selectively chemoattract naive T and immature den-
dritic cells. J Leukoc Biol 2000, 68:9–14.
57. van Wetering S, Sterk PJ, Rabe KF, Hiemstra PS: Defensins: key
players or bystanders in infection, injury, and repair in the lung? J
Allergy Clin Immunol 1999, 104:1131–1138.
58. Yang D, Chertov O, Bykovskaia S, Chen Q, Buffo M, Shogan J, Ander-
• son M, Schroder J, Wang J, Howard O, Oppenheim J: b b-defensins: 
linking innate and adaptive immunity through dendritic and T cell 
CCR6. Science 1999, 286:525–528.
These authors found activities of human b-defensins that are beyond the
direct antimicrobial activity and have stimulatory consequences for the
adaptive immune system.
59. Smith J, Travis S, Greenberg E, Welsh M: Cystic fibrosis airway 
•• epithelia fail to kill bacteria because of abnormal airway surface 
fluid. Cell 1996, 85:229–236.
Classic publication that showed that cystic fibrosis airway secretions lack
antimicrobial activity in experimental systems. This paper, together with
[17••], stimulated the recent interest in the role of antimicrobial peptides in
lung disease.
60. Bals R, Weiner D, Wilson J: The innate immune system in cystic
fibrosis lung disease. J Clin Invest 1999, 103:303–307.
61. Lillard JW Jr, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR:
Mechanisms for induction of acquired host immunity by neu-
trophil peptide defensins. Proc Natl Acad Sci USA 1999,
96:651–656.
62. Coyle AJ, Uchida D, Ackerman SJ, Mitzner W, Irvin CG: Role of
cationic proteins in the airway. Hyperresponsiveness due to airway
inflammation. Am J Respir Crit Care Med 1994, 150:S63–S71.
63. Boman HG: Peptide antibiotics and their role in innate immunity.
Annu Rev Immunol 1995, 13:61–92.
Author’s affiliation: Hospital of the University of Munich – Campus
Grosshadern, Munich, Germany
Correspondence: Robert Bals, MD, PhD, Hospital of the University of
Munich – Campus Grosshadern, Medizinische Klinik und Poliklinik I,
Schwerpunkt Pneumologie, Marchioninistrasse 15, 81377 München,
Germany. Tel: +49 89 7095 3071; fax: +49 89 7095 8877; e-mail:
rbals@med1.med.uni-muenchen.de
Respiratory Research    Vol 1 No 3 Bals